Antibiotic Pharmacology Classification for NEET PG 2026

Antibiotic pharmacology is the second-most-tested topic in NEET PG pharmacology after autonomic drugs. Examiners rotate through three patterns: mechanism of action vignettes ("which drug binds the 50S ribosome?"), resistance mechanism stems ("MRSA achieves resistance by..."), and clinical pairing problems ("which antibiotic for ESBL E. coli pyelonephritis?"). Mastering this NEETPGAI guide gives you reflex answers to all three.

This deep dive covers every major antibiotic class with their canonical mechanism, spectrum, characteristic adverse effects, and resistance patterns relevant to MRSA, VRE, ESBL, CRE, and Pseudomonas. Reinforce concepts with the microbiology high-yield topics guide and structured MCQ practice on the Pharmacology hub.

Beta-lactam antibiotics

Beta-lactams share a four-membered beta-lactam ring that mimics the D-Ala-D-Ala terminus of peptidoglycan, irreversibly acylating bacterial transpeptidases (penicillin-binding proteins, PBPs) and blocking cell wall cross-linking. They are bactericidal against actively dividing organisms.

Penicillins

Beta-lactamase inhibitors: clavulanic acid, sulbactam, tazobactam, avibactam, vaborbactam, relebactam. They have minimal intrinsic activity but protect the partner antibiotic.

Cephalosporins

The five-generation classification roughly tracks expanding Gram-negative spectrum (with loss of Gram-positive coverage until the 5th generation reclaims it).

Cephalosporin pearls:

• All cephalosporins LACK coverage of LAME organisms — Listeria, Atypicals (Mycoplasma, Chlamydia, Legionella), MRSA, Enterococcus.
• Ceftriaxone has biliary excretion — safe in renal failure but causes biliary pseudolithiasis in neonates (give cefotaxime instead).
• Cefoperazone, cefamandole, cefotetan have an MTT side chain → disulfiram-like reaction with alcohol and hypoprothrombinemia.

Carbapenems

Imipenem, meropenem, ertapenem, doripenem. They have the broadest spectrum among beta-lactams, covering most Gram-positive (except MRSA, VRE), Gram-negative (including ESBLs, AmpC), and anaerobes.

• Imipenem is co-formulated with cilastatin (inhibits renal dehydropeptidase-1 to prevent imipenem degradation).
• Ertapenem does NOT cover Pseudomonas, Acinetobacter, or Enterococcus — major exam trap.
• Lower seizure threshold (especially imipenem) — caution in epilepsy and renal impairment.

Monobactams

Aztreonam is the only marketed monobactam. Active only against aerobic Gram-negatives (no Gram-positive or anaerobic coverage). Crucially, it does NOT cross-react with other beta-lactams — useful in penicillin-allergic patients (except those allergic to ceftazidime, which shares the same R1 side chain).

Protein synthesis inhibitors

Bacterial ribosome differs from eukaryotic — 70S (30S + 50S) vs 80S (40S + 60S). Antibiotics exploit this difference at three levels.

30S ribosomal subunit

Aminoglycosides (gentamicin, tobramycin, amikacin, streptomycin, neomycin):

• Mechanism: Bind 30S, cause misreading of mRNA → faulty proteins; require oxygen-dependent uptake (no anaerobic activity)
• Spectrum: Gram-negative aerobes, synergy with beta-lactams against Enterococcus and Staphylococcus
• PK/PD: Concentration-dependent killing + post-antibiotic effect → once-daily extended-interval dosing
• ADRs: Nephrotoxicity (proximal tubule, reversible), ototoxicity (cochlear and vestibular, irreversible), neuromuscular blockade (myasthenia gravis caution)

Tetracyclines (doxycycline, minocycline, tigecycline):

• Mechanism: Bind 30S, prevent aminoacyl-tRNA attachment
• Spectrum: Atypicals (Mycoplasma, Chlamydia), Rickettsia, Lyme disease, Brucella, Vibrio cholerae; tigecycline covers MRSA, VRE
• ADRs: Photosensitivity, teeth staining and enamel hypoplasia in <8 years, contraindicated in pregnancy; minocycline causes vestibular toxicity and DRESS

50S ribosomal subunit

Macrolides (azithromycin, clarithromycin, erythromycin):

• Mechanism: Bind 23S rRNA in 50S, block translocation
• Spectrum: Atypical pneumonia (Legionella, Mycoplasma, Chlamydophila), pertussis, Helicobacter (clarithromycin in triple therapy), MAC prophylaxis (azithromycin)
• ADRs: QT prolongation, GI motility (erythromycin = motilin agonist), hepatotoxicity (cholestatic), drug interactions (CYP3A4 inhibition — clarithromycin worst, azithromycin minimal)

Chloramphenicol: binds 50S; rarely used due to aplastic anemia (idiosyncratic, fatal) and gray baby syndrome in neonates (immature UDP-glucuronyl transferase).

Clindamycin: binds 50S; covers anaerobes above the diaphragm (lung abscess), MSSA, GAS; suppresses toxin production in toxic shock and necrotizing fasciitis. Highest C. difficile colitis risk.

Linezolid (and tedizolid) — oxazolidinones:

• Mechanism: Bind 23S rRNA, prevent 70S initiation complex formation (unique site)
• Spectrum: MRSA, VRE, drug-resistant TB
• ADRs: Reversible thrombocytopenia (after 2 weeks), peripheral and optic neuropathy, lactic acidosis, MAO inhibition → serotonin syndrome with SSRIs

Cell wall and membrane agents (non-beta-lactam)

Glycopeptides

Vancomycin (IV) and teicoplanin bind D-Ala-D-Ala terminus of peptidoglycan precursors, blocking transglycosylation and transpeptidation.

• Spectrum: Gram-positive only — MRSA, MR-CoNS, Enterococcus (not VRE), C. difficile (oral, non-absorbable)
• VRE mechanism: Replaces D-Ala-D-Ala with D-Ala-D-Lac (1000-fold reduced affinity) — vanA, vanB genes
• ADRs: Nephrotoxicity, ototoxicity, red man syndrome (histamine release from rapid infusion — slow infusion, NOT type I hypersensitivity), DRESS
• Monitoring: Trough levels (15–20 µg/mL for serious infections); newer: AUC/MIC monitoring

Lipopeptides

Daptomycin (IV): inserts into Gram-positive cell membrane → depolarisation and rapid bactericidal action.

• Spectrum: MRSA, VRE, complicated SSTI, S. aureus bacteremia, right-sided endocarditis
• CRITICAL: Inactivated by lung surfactant — DO NOT use for pneumonia
• ADRs: Myopathy (hold statins), eosinophilic pneumonia, elevated CPK (monitor weekly)

Polymyxins

Polymyxin B and colistin (polymyxin E): detergents that disrupt Gram-negative outer membrane.

• Last-resort for carbapenem-resistant Enterobacteriaceae (CRE) and MDR Pseudomonas/Acinetobacter
• ADRs: Severe nephrotoxicity, neurotoxicity (paresthesia, neuromuscular blockade)

Nucleic acid synthesis inhibitors

Fluoroquinolones

Ciprofloxacin, levofloxacin, moxifloxacin, ofloxacin — inhibit bacterial DNA gyrase (topoisomerase II, predominant Gram-negative target) and topoisomerase IV (Gram-positive target).

Black box warnings (FDA):

• Tendinopathy and tendon rupture (Achilles), worse with corticosteroids
• Aortic aneurysm and dissection — avoid in elderly with vascular disease
• Peripheral neuropathy (may be permanent)
• Dysglycemia (especially with sulfonylureas)
• CNS effects, exacerbation of myasthenia gravis
• QT prolongation

Drug interactions: Chelate divalent/trivalent cations (Ca, Mg, Al, Fe, Zn) — separate by 2 hours from antacids, dairy, sucralfate.

Rifamycins

Rifampin (anti-TB), rifabutin (HIV co-infection — less CYP induction), rifaximin (non-absorbable, hepatic encephalopathy and traveler's diarrhea).

• Mechanism: Inhibits bacterial DNA-dependent RNA polymerase (rpoB)
• CYP induction: Massive — interacts with warfarin, OCPs, anti-rejection drugs, ART; orange-red discoloration of body fluids

Nitroimidazoles and nitrofurans

Metronidazole: activated by anaerobic bacteria/protozoa to reactive intermediates that damage DNA. Spectrum: anaerobes (B. fragilis below diaphragm), Trichomonas, Giardia, Entamoeba, C. difficile (oral, no longer first-line). ADR: disulfiram reaction with alcohol, peripheral neuropathy with prolonged use.

Nitrofurantoin: uncomplicated UTI only; concentrates in urine but not tissues. Avoid in CrCl <30, pyelonephritis, third-trimester pregnancy (hemolysis in G6PD-deficient neonate).

Antifolates

Trimethoprim-sulfamethoxazole (cotrimoxazole) — sequential blockade of folate synthesis.

• Sulfamethoxazole inhibits dihydropteroate synthase (PABA → DHF)
• Trimethoprim inhibits dihydrofolate reductase (DHF → THF)
• Spectrum: Pneumocystis jirovecii (treatment and prophylaxis), Stenotrophomonas, Nocardia, community MRSA SSTI, UTI
• ADRs: Stevens-Johnson syndrome, hyperkalemia (trimethoprim blocks ENaC), megaloblastic anemia, kernicterus in neonates

Resistance mechanisms — the big four

1. Enzymatic inactivation — beta-lactamases (penicillinase, ESBL, AmpC, carbapenemase like KPC, NDM-1, OXA), aminoglycoside-modifying enzymes, chloramphenicol acetyltransferase
2. Target modification — MRSA mecA → PBP2a (low-affinity for beta-lactams), VRE vanA → D-Ala-D-Lac (low-affinity for vancomycin), ribosomal methylation (erm gene → MLSb resistance to macrolides, lincosamides, streptogramins B), gyrA mutations (fluoroquinolones)
3. Reduced uptake — porin loss in Gram-negatives (OprD loss → carbapenem resistance in Pseudomonas)
4. Efflux pumps — MexAB-OprM in Pseudomonas, NorA in Staphylococcus, TetA in tetracycline resistance

Coverage of resistant organisms

High-yield NEET PG MCQ traps

1. Ertapenem does NOT cover Pseudomonas, Acinetobacter, or Enterococcus — only carbapenem with this gap.
2. Daptomycin is inactivated by surfactant — never for pneumonia.
3. Aztreonam is safe in penicillin allergy except ceftazidime allergy (shared R1 side chain).
4. Cefoxitin and cefotetan cover anaerobes (only 2nd-generation cephalosporins to do so).
5. Vancomycin for C. difficile is given ORALLY — IV vancomycin does not reach the colonic lumen.
6. Aminoglycosides lack anaerobic activity (oxygen-dependent uptake).
7. Fluoroquinolone tendinopathy is worsened by corticosteroids; Achilles tendon most common.
8. Metronidazole + alcohol = disulfiram reaction (no longer in 2024 FDA labeling but still tested).
9. Doxycycline is the only tetracycline not requiring renal dose adjustment.
10. Linezolid + SSRI = serotonin syndrome (linezolid is a weak MAO inhibitor).

Recent updates and guidelines

• IDSA 2024 MRSA guidelines — vancomycin AUC/MIC monitoring (target 400–600) replaces trough-only monitoring for serious infections.
• WHO 2024 AWaRe classification — updated Access, Watch, Reserve antibiotic categories for stewardship.
• CRE treatment — ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam, and cefiderocol have largely supplanted polymyxin-based regimens.
• Indian ICMR antibiotic guidelines 2023 — emphasise narrow-spectrum first-line therapy and de-escalation; relevant for FMGE and INI-CET in addition to NEET PG.
• Long-acting glycopeptides — dalbavancin and oritavancin (single-dose for SSTI) — increasingly tested.

Frequently asked questions

Which antibiotics cover MRSA?

Vancomycin (IV), linezolid (oral and IV), daptomycin (skin and bacteremia, NOT pneumonia — surfactant inactivates it), ceftaroline (5th-generation cephalosporin), tigecycline, and trimethoprim-sulfamethoxazole or doxycycline for community-acquired MRSA skin infections.

What is the mechanism of beta-lactam antibiotic resistance?

Three main mechanisms: beta-lactamase production (most common — penicillinases, ESBLs, AmpC, carbapenemases like KPC and NDM), altered penicillin-binding proteins (MRSA mecA gene → PBP2a, low-affinity), and reduced porin permeability or efflux pumps in Gram-negatives.

Which aminoglycoside is least nephrotoxic?

Streptomycin is generally considered the least nephrotoxic aminoglycoside, while neomycin is the most nephrotoxic (used only topically and orally for bowel sterilization). Once-daily extended-interval dosing reduces toxicity for gentamicin and tobramycin while maintaining efficacy via concentration-dependent killing.

When is linezolid preferred over vancomycin for MRSA pneumonia?

Linezolid is preferred over vancomycin when patients have renal failure, persistent MRSA bacteremia despite adequate vancomycin levels, or vancomycin MIC ≥2. It achieves superior lung tissue penetration. Watch for thrombocytopenia (over 2 weeks use), serotonin syndrome with SSRIs, and lactic acidosis.

Which fluoroquinolone has best anti-pseudomonal activity?

Ciprofloxacin has the most potent anti-pseudomonal activity among fluoroquinolones and remains the preferred oral agent for Pseudomonas aeruginosa coverage. Levofloxacin has moderate activity. Moxifloxacin has poor anti-pseudomonal activity but excellent anaerobic and respiratory pathogen coverage.

---

Written by: NEETPGAI Editorial Team Reviewed by: Pending SME Review Last reviewed: April 2026